BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 9644302)

  • 21. Therapeutic use of granulocyte-colony stimulating factor could conceal residual malignant cells in patients with AML1/ETO+ acute myelogenous leukemia.
    Moon HW; Shin S; Kim HY; Kim YR; Cho HI; Yoon SS; Park S; Kim BK; Chun H; Kim HC; Park CJ; Min YH; Lee DS
    Leukemia; 2006 Aug; 20(8):1408-13. PubMed ID: 16791271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse.
    Ehlers S; Herbst C; Zimmermann M; Scharn N; Germeshausen M; von Neuhoff N; Zwaan CM; Reinhardt K; Hollink IH; Klusmann JH; Lehrnbecher T; Roettgers S; Stary J; Dworzak M; Welte K; Creutzig U; Reinhardt D
    J Clin Oncol; 2010 May; 28(15):2591-7. PubMed ID: 20406937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study.
    Usuki K; Urabe A; Masaoka T; Ohno R; Mizoguchi H; Hamajima N; Miyazaki T; Niitsu Y; Yoshida Y; Miura A; Shibata A; Abe T; Miura Y; Ikeda Y; Nomura T; Nagao T; Saitou H; Shirakawa S; Ohkuma M; Matsuda T; Nakamura T; Horiuchi A; Kuramoto A; Kimura I; Irino S; Niho Y; Takatsuki K; Tomonaga M; Uchino H; Takaku F;
    Br J Haematol; 2002 Jan; 116(1):103-12. PubMed ID: 11841402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): estimates from a Southwest Oncology Group clinical trial.
    Bennett CL; Hynes D; Godwin J; Stinson TJ; Golub RM; Appelbaum FR;
    Cancer Invest; 2001; 19(6):603-10. PubMed ID: 11486703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination chemotherapy with G-CSF, M-CSF and EPO: successful treatment for acute myelogenous leukemia without blood transfusion at lower medical costs.
    Kaito K; Kobayashi M; Sakamoto M; Shimada T; Masuoka H; Nishiwaki K; Saeki A; Sekita T; Otsubo H; Hosoya T
    Acta Haematol; 1998; 100(1):57-60. PubMed ID: 9691149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Granulocyte colony stimulating factor priming chemotherapy is more effective than standard chemotherapy as salvage therapy in relapsed acute myeloid leukemia.
    Shen Y; He A; Wang F; Bai J; Wang J; Zhao W; Zhang W; Cao X; Chen Y; Liu J; Ma X; Chen H; Feng Y; Yang Y
    Med Clin (Barc); 2018 Nov; 151(9):339-344. PubMed ID: 29292108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Complete remission induced by combined treatment with all-trans retinoic acid (ATRA) and granulocyte colony-stimulating factor (G-CSF) in a patient with relapsed acute promyelocytic leukemia].
    Wakayama T; Furuya H; Takagi C; Ichiba S; Kato Y
    Rinsho Ketsueki; 1994 Nov; 35(11):1315-21. PubMed ID: 7529843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of cytokines in the treatment of acute myelocytic leukemia: a critical review.
    Geller RB
    J Clin Oncol; 1996 Apr; 14(4):1371-82. PubMed ID: 8648396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful second autologous blood stem cell transplantation after G-CSF-combined conditioning for the treatment of high-risk acute myelogenous leukemia.
    Takamatsu Y; Teshima T; Akashi K; Inaba S; Harada M; Niho Y
    Bone Marrow Transplant; 1994 Mar; 13(3):325-7. PubMed ID: 7515302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Production of granulocyte colony stimulating factor, granulocyte macrophage colony stimulating factor, and tumor necrosis factor alpha during remission and infections in patients with acute leukemia.
    Duru F; Ertem U; Taçyildiz N; Kirazli S
    J Med; 1995; 26(5-6):241-52. PubMed ID: 8721901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Remission induction of refractory anaemia with excess blasts in transformation by sole treatment with granulocyte colony-stimulating factor with persistent chromosomal abnormality.
    Kondo H; Kasahara Y; Mori A
    Acta Haematol; 2002; 107(3):177-81. PubMed ID: 11978940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group.
    Dombret H; Chastang C; Fenaux P; Reiffers J; Bordessoule D; Bouabdallah R; Mandelli F; Ferrant A; Auzanneau G; Tilly H
    N Engl J Med; 1995 Jun; 332(25):1678-83. PubMed ID: 7539109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group.
    Zittoun R; Suciu S; Mandelli F; de Witte T; Thaler J; Stryckmans P; Hayat M; Peetermans M; Cadiou M; Solbu G; Petti MC; Willemze R
    J Clin Oncol; 1996 Jul; 14(7):2150-9. PubMed ID: 8683249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human granulocyte colony-stimulating factor receptors in acute myelogenous leukemia.
    Kondo S; Okamura S; Asano Y; Harada M; Niho Y
    Eur J Haematol; 1991 Apr; 46(4):223-30. PubMed ID: 1707827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
    Estey EH; Kantarjian HM; O'Brien S; Kornblau S; Andreeff M; Beran M; Pierce S; Keating M
    Cytokines Mol Ther; 1995 Mar; 1(1):21-8. PubMed ID: 9384660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The potential prognostic influence of granulocyte-colony stimulating factor in acute leukemia].
    Liu XM; Chen YZ; Huang MJ; Liu X; Guo JR
    Zhonghua Nei Ke Za Zhi; 2005 Jul; 44(7):518-21. PubMed ID: 16080844
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
    Bruserud O; Foss B; Petersen H
    Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Timed-sequential chemotherapy with concomitant granulocyte colony-stimulating factor for newly diagnosed de novo acute myelogenous leukemia.
    He XY; Pohlman B; Lichtin A; Rybicki L; Kalaycio M
    Leukemia; 2003 Jun; 17(6):1078-84. PubMed ID: 12764371
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proliferative response of human acute myeloid leukemia cells and normal marrow enriched progenitor cells to human recombinant growth factors IL-3, GM-CSF and G-CSF alone and in combination.
    Lemoli RM; Gulati SC; Strife A; Lambek C; Perez A; Clarkson BD
    Leukemia; 1991 May; 5(5):386-91. PubMed ID: 1709711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.